FI115048B - Menetelmä aminohappoon liitettyjen typpisinappijohdannaisten valmistamiseksi - Google Patents

Menetelmä aminohappoon liitettyjen typpisinappijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI115048B
FI115048B FI950230A FI950230A FI115048B FI 115048 B FI115048 B FI 115048B FI 950230 A FI950230 A FI 950230A FI 950230 A FI950230 A FI 950230A FI 115048 B FI115048 B FI 115048B
Authority
FI
Finland
Prior art keywords
amino
bis
chloroethyl
formula
compound
Prior art date
Application number
FI950230A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI950230L (fi
FI950230A0 (fi
Inventor
Robert Ian Dowell
Philip John Burke
Anthony Brian Mauger
Caroline Joy Springer
Original Assignee
Astrazeneca Ab
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215636A external-priority patent/GB9215636D0/en
Priority claimed from GB939310884A external-priority patent/GB9310884D0/en
Application filed by Astrazeneca Ab, Cancer Res Campaign Tech filed Critical Astrazeneca Ab
Publication of FI950230L publication Critical patent/FI950230L/fi
Publication of FI950230A0 publication Critical patent/FI950230A0/fi
Application granted granted Critical
Publication of FI115048B publication Critical patent/FI115048B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66Methanesulfonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
FI950230A 1992-07-23 1995-01-19 Menetelmä aminohappoon liitettyjen typpisinappijohdannaisten valmistamiseksi FI115048B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9215636 1992-07-23
GB929215636A GB9215636D0 (en) 1992-07-23 1992-07-23 Chemical compounds
GB939310884A GB9310884D0 (en) 1993-05-26 1993-05-26 Chemical compounds
GB9310884 1993-05-26
PCT/GB1993/001560 WO1994002450A1 (en) 1992-07-23 1993-07-23 Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumours
GB9301560 1993-07-23

Publications (3)

Publication Number Publication Date
FI950230L FI950230L (fi) 1995-01-19
FI950230A0 FI950230A0 (fi) 1995-01-19
FI115048B true FI115048B (fi) 2005-02-28

Family

ID=26301303

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950230A FI115048B (fi) 1992-07-23 1995-01-19 Menetelmä aminohappoon liitettyjen typpisinappijohdannaisten valmistamiseksi

Country Status (24)

Country Link
US (6) US5405990A (cs)
EP (1) EP0651740B1 (cs)
JP (1) JP3541037B2 (cs)
KR (1) KR100268654B1 (cs)
AT (1) ATE172450T1 (cs)
AU (1) AU681349B2 (cs)
CA (1) CA2101104C (cs)
CZ (1) CZ287028B6 (cs)
DE (1) DE69321729T2 (cs)
DK (1) DK0651740T3 (cs)
ES (1) ES2123662T3 (cs)
FI (1) FI115048B (cs)
GB (1) GB9314960D0 (cs)
HU (1) HUT69288A (cs)
IL (1) IL106459A (cs)
MY (1) MY111635A (cs)
NZ (1) NZ254864A (cs)
PH (1) PH30004A (cs)
PL (1) PL174617B1 (cs)
RU (1) RU2129542C1 (cs)
SK (1) SK281338B6 (cs)
TW (1) TW272971B (cs)
WO (1) WO1994002450A1 (cs)
ZW (1) ZW9293A1 (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
WO1995002420A2 (en) * 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9426133D0 (en) * 1994-12-23 1995-02-22 Zeneca Ltd Chemical compounds
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2000047236A1 (en) * 1999-02-12 2000-08-17 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
AU7570201A (en) * 2000-07-26 2002-02-05 Riley Patrick Anthony Phenylethylamine derivatives and their use in the treatment of melanoma
RU2177718C1 (ru) * 2000-10-27 2002-01-10 Кировская государственная медицинская академия Способ установления факта удара тупым твердым предметом по волосистой части головы через тканый и нетканый материал
RU2181261C1 (ru) * 2000-10-27 2002-04-20 Кировская государственная медицинская академия Способ определения контактной поверхности тупого твердого предмета при ударе по волосистой части головы
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
RU2231063C2 (ru) * 2001-10-04 2004-06-20 Войсковая часть 61469 Способ оценки проницаемости иприта через защитные материалы
WO2003050124A1 (en) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2283869A3 (en) 2002-07-15 2012-06-27 Board of Regents, The University of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
US20060148893A1 (en) * 2003-06-10 2006-07-06 Blanc Jean-Baptiste E Chemical compounds
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
WO2007038658A2 (en) * 2005-09-26 2007-04-05 Medarex, Inc. Antibody-drug conjugates and methods of use
PL1940789T3 (pl) 2005-10-26 2012-04-30 Squibb & Sons Llc Metody i związki do otrzymywania analogów cc-1065
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2121667B1 (en) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemical linkers with single amino acids and conjugates thereof
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
TW201900606A (zh) * 2017-05-15 2019-01-01 日商旭化成股份有限公司 異氰酸酯的製造方法
CN113845448B (zh) * 2021-10-20 2023-07-07 厦门大学 一种放射性18f标记化合物及其应用
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) * 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
GB8920011D0 (en) * 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
EP0638123B1 (en) * 1991-10-23 2006-12-27 Cancer Research Technology Limited Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
RU2129542C1 (ru) 1999-04-27
US6277880B1 (en) 2001-08-21
CA2101104A1 (en) 1994-01-24
JP3541037B2 (ja) 2004-07-07
AU681349B2 (en) 1997-08-28
HUT69288A (en) 1995-09-28
DK0651740T3 (da) 1999-06-28
IL106459A (en) 1998-02-08
RU95105246A (ru) 1997-04-27
MY111635A (en) 2000-10-31
HU9500145D0 (en) 1995-03-28
DE69321729D1 (de) 1998-11-26
FI950230L (fi) 1995-01-19
ZW9293A1 (en) 1994-03-30
GB9314960D0 (en) 1993-09-01
US5660829A (en) 1997-08-26
US5405990A (en) 1995-04-11
CZ15195A3 (en) 1995-11-15
AU4715693A (en) 1994-02-14
EP0651740A1 (en) 1995-05-10
ATE172450T1 (de) 1998-11-15
EP0651740B1 (en) 1998-10-21
CA2101104C (en) 2007-01-23
NZ254864A (en) 1996-11-26
SK281338B6 (sk) 2001-02-12
FI950230A0 (fi) 1995-01-19
JPH07509461A (ja) 1995-10-19
KR100268654B1 (ko) 2000-10-16
DE69321729T2 (de) 1999-03-18
US5714148A (en) 1998-02-03
IL106459A0 (en) 1994-11-11
PL174617B1 (pl) 1998-08-31
WO1994002450A1 (en) 1994-02-03
CZ287028B6 (en) 2000-08-16
US5587161A (en) 1996-12-24
US5958971A (en) 1999-09-28
PL307226A1 (en) 1995-05-15
PH30004A (en) 1996-10-29
SK6995A3 (en) 1995-07-11
ES2123662T3 (es) 1999-01-16
HK1002683A1 (en) 1998-09-11
TW272971B (cs) 1996-03-21

Similar Documents

Publication Publication Date Title
FI115048B (fi) Menetelmä aminohappoon liitettyjen typpisinappijohdannaisten valmistamiseksi
US5728868A (en) Prodrugs of protein tyrosine kinase inhibitors
EP0846680A1 (en) Cationic lipids for gene therapy
US6005002A (en) Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production
AU716920B2 (en) Enediyne compounds
KR20140135832A (ko) 아미노산 지질
US20160251320A1 (en) Compounds
KR20070019941A (ko) 글리세롤 유도체로 수식된 화합물
US20100240747A1 (en) Motuporamine Mimic Agents
HK1002683B (en) Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumours
MXPA97008111A (es) Lipidos cationicos para terapia genica

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115048

Country of ref document: FI

MA Patent expired